CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Telesta Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Telesta Therapeutics Inc
2600 Alfred-Nobel Blvd Suite 301
Phone: (514) 697-6636p:514 697-6636 SAINT-LAURENT, QC  H4S 0A9  Canada Fax: (514) 697-7966f:514 697-7966
This company was Merged or Acquired on 10/31/2016.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Telesta Therapeutics Inc. is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer. The Company owns a manufacturing facility for MCNA at Montreal, Quebec.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20166/30/2016Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board James M.Rae 7/27/2012 7/27/2012
Chief Executive Officer, Chief Scientific Officer Michael J.Berendt 67 1/1/2014 11/5/2013
Chief Financial Officer Brian R.Ford 67 9/16/2009 9/16/2009
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Bioniche Therapeutics
Bioniche Urology IP Inc.
Econiche Corp.

General Information
Stock Exchange: TSE
Fax Number: (514) 697-7966


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023